Ravi Jandhyala

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 37

Top Topics

Age Related Macular Degeneration

Nursing Students

Cross Sectional

Top Venues

Current medical research and opinion

BMC medical research methodology

Pharmaceutical medicine

Orphanet journal of rare diseases

This page only lists publications with an associated author ORCID identifier.

Publications

Sobha Sivaprasad, C Bailey, Louise Downey, Rose Gilbert, Richard Gale, Ajay Kotagiri, Sajjad Mahmood, Peter Morgan-Warren, Jackie Napier, Nirodhini Narendran, Ian Pearce, Christina Rennie, James Talks, Radek Wojcik, Ravi Jandhyala
Real-world service costs for neovascular-AMD clinics in the United Kingdom: structured literature review and scenario analysis. Current medical research and opinion (2024)
Sobha Sivaprasad, Clare Bailey, Louise Downey, Rose Gilbert, Richard Gale, Ajay Kotagiri, Sajjad Mahmood, Peter Morgan-Warren, Jackie Napier, Nirodhini Narendran, Ian Pearce, Christina Rennie, James Talks, Radek Wojcik, Ravi Jandhyala
Real-world service costs for neovascular-AMD clinics in the United Kingdom: structured literature review and scenario analysis. Current medical research and opinion (2024)
Sobha Sivaprasad, Clare Bailey, Louise Downey, Rose Gilbert, Richard Gale, Ajay Kotagiri, Sajjad Mahmood, Peter Morgan-Warren, Jackie Napier, Nirodhini Narendran, Ian Pearce, Christina Rennie, James Talks, Radek Wojcik, Ravi Jandhyala
Real-world service costs for neovascular-AMD clinics in the United Kingdom: structured literature review and scenario analysis. Current medical research and opinion 40 (7) (2024)
Ravi Jandhyala
Development, validation and implementation of the medical affairs pharmaceutical physician work-related quality of life instrument. Current medical research and opinion (2023)
Ravi Jandhyala
Development of a definition for real-world evidence using the Jandhyala method for observing consensus opinion among medical affairs pharmaceutical physicians. Current medical research and opinion (2023)
Ravi Jandhyala
Neutral theory: applicability and neutrality of clinical study endpoints where a disease-specific instrument is available. BMC medical research methodology 23 (1) (2023)
Ravi Jandhyala
Commercial impact of adding real-world evidence to clinical trials at regulatory approval: A Markovian-like transition model. Current medical research and opinion (2023)
Ravi Jandhyala
Development of a definition for real-world evidence using the Jandhyala method for observing consensus opinion among medical affairs pharmaceutical physicians. Current medical research and opinion (2023)
Steve Freedman, Enrique de Madaria, Eric Bruckert, Matthias Löhr, Vinciane Rebours, Ravi Jandhyala
Observed consensus on research priorities for the hypertriglyceridemia patient registry. Current medical research and opinion (2023)
Ravi Jandhyala
Guest editor foreword: real-world evidence and medical affairs. Current medical research and opinion (2023)
Ravi Jandhyala
Neutral theory: applicability and neutrality of clinical study endpoints where a disease-specific instrument is available. BMC medical research methodology 23 (1) (2023)
Steve Freedman, Enrique de Madaria, Eric Bruckert, Matthias Löhr, Vinciane Rebours, Ravi Jandhyala
A protocol for an international, multicenter, prospective, non-interventional observational registry for patients with hypertriglyceridemia. Current medical research and opinion (2023)
Ravi Jandhyala, Raj Rout
Observing expert opinion of medical affairs pharmaceutical physicians on the value of their clinical experience to the pharmaceutical industry using the Jandhyala method. Current medical research and opinion (2023)
Ravi Jandhyala
Commercial impact of adding real-world evidence to clinical trials at regulatory approval: a Markovian-like transition model. Current medical research and opinion (2023)
Irene Marcilla-Toribio, Maria Martinez-Andres, Maria Leopolda Moratalla-Cebrian, Ravi Jandhyala, Omolade Femi-Ajao, null Eva Maria Galan-Moya
Adaptation and validation of the PAC19-QoL specific quality of life questionnaire for the Spanish population with Long COVID. Current medical research and opinion (2023)
Ravi Jandhyala
Development, validation and implementation of the medical affairs pharmaceutical physician work-related quality of life instrument. Current medical research and opinion (2023)
Ravi Jandhyala, Raj Rout
Observing expert opinion of medical affairs pharmaceutical physicians on the value of their clinical experience to the pharmaceutical industry using the Jandhyala method. Current medical research and opinion (2023)
Archana Chatterjee, Karita Ambrose, David H Canaday, Shirley Delair, Ngozi Ezike, Victor C Huber, Ravi Jhaveri, Ann-Christine Nyquist, Abigail J Sporer, Meera Varman, Renuga Vivekanandan, Radek Wojcik, Ravi Jandhyala
The association between influenza vaccine effectiveness and egg-based manufacturing technology: literature review and US expert consensus. Current medical research and opinion (2023)
Ravi Jandhyala
Neutral theory: applicability and neutrality of clinical study endpoints where a disease-specific instrument is available. BMC medical research methodology 23 (1) (2023)
Ravi Jandhyala
Professional qualifications of medical affairs pharmaceutical physicians and other internal stakeholders in the pharmaceutical industry. F1000Research 11 (2022)
Ravi Jandhyala
Development and Validation of the Medical Affairs Pharmaceutical Physician Value (MAPPval) Instrument. Pharmaceutical medicine 36 (1) (2022)
Steve Freedman, Enrique de Madaria, Vikesh K Singh, Eric Bruckert, Matthias Löhr, Robert Sutton, Vinciane Rebours, Richard Jones, Ravi Jandhyala
A simple core dataset for triglyceride-induced acute pancreatitis. Current medical research and opinion (2022)
Ravi Jandhyala
Concordance between the schedule for the evaluation of individual quality of life-direct weighting (SEIQoL-DW) and the EuroQoL-5D (EQ-5D) measures of quality of life outcomes in adults with X-linked hypophosphatemia. Orphanet journal of rare diseases 17 (1) (2022)
Ravi Jandhyala
Professional qualifications of medical affairs pharmaceutical physicians and other internal stakeholders in the pharmaceutical industry. F1000Research 11 (2022)
Ravi Jandhyala
The effect of adding real-world evidence to regulatory submissions on the breadth of population indicated for rare disease medicine treatment by the European Medicines Agency. Journal of pharmaceutical policy and practice 15 (1) (2022)
Ravi Jandhyala
Influence of Pharmaceutical Company Engagement Activities on the Decision to Prescribe: A Pilot Survey of UK Rare Disease Medicine Prescribers. Pharmaceutical medicine 34 (2) (2021)
Ravi Jandhyala
A medicine adoption model for assessing the expected effects of additional real-world evidence (RWE) at product launch. Current medical research and opinion 37 (9) (2021)
Thibaud Damy, Isabel Conceição, Pablo García-Pavía, Julian David Gillmore, Ravi Jandhyala, Jan Sabbat, Jonas Wixner, Teresa Coelho
A simple core dataset and disease severity score for hereditary transthyretin (ATTRv) amyloidosis. Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis 28 (3) (2021)
Ravi Jandhyala
Neutral theory: applicability and neutrality of using generic health-related quality of life tools in diseases or conditions where specific tools are available. BMC medical research methodology 21 (1) (2021)
Ravi Jandhyala
Design, validation and implementation of the post-acute (long) COVID-19 quality of life (PAC-19QoL) instrument. Health and quality of life outcomes 19 (1) (2021)
Raul Ortiz de Lejarazu-Leonardo, Emanuele Montomoli, Radek Wojcik, Solomon Christopher, Anne Mosnier, Elena Pariani, Antoni Trilla Garcia, Helmut Fickenscher, Barbara C Gärtner, Ravi Jandhyala, Maria Zambon, Catherine Moore
Estimation of Reduction in Influenza Vaccine Effectiveness Due to Egg-Adaptation Changes-Systematic Literature Review and Expert Consensus. Vaccines 9 (11) (2021)
Ravi Jandhyala
The multiple stakeholder approach to real-world evidence (RWE) generation: observing multidisciplinary expert consensus on quality indicators of rare disease patient registries (RDRs). Current medical research and opinion 37 (7) (2021)
Ravi Jandhyala
Comment on: "Patient Registries: An Underused Resource for Medicines Evaluation: Operational Proposals for Increasing the Use of Patient Registries in Regulatory Assessments". Drug safety 42 (12) (2020)
Ravi Jandhyala
A novel method for observing proportional group awareness and consensus of items arising from list-generating questioning. Current medical research and opinion 36 (5) (2020)
Ravi Jandhyala
Delphi, non-RAND modified Delphi, RAND/UCLA appropriateness method and a novel group awareness and consensus methodology for consensus measurement: a systematic literature review. Current medical research and opinion 36 (11) (2020)
Ravi Jandhyala, Solomon Christopher
Factors Influencing the Generation of Evidence from Simple Data Held in International Rare Disease Patient Registries. Pharmaceutical medicine 34 (1) (2020)
Raja Padidela, Ola Nilsson, Outi Makitie, Signe Beck-Nielsen, Gema Ariceta, Dirk Schnabel, Maria Luisa Brandi, Annemieke Boot, Elena Levtchenko, Michael Smyth, Ravi Jandhyala, Zulf Mughal
The international X-linked hypophosphataemia (XLH) registry (NCT03193476): rationale for and description of an international, observational study. Orphanet journal of rare diseases 15 (1) (2020)